Last Posted: May 03, 2019
- Making the invisible visible: New method opens unexplored realms for liquid biopsies
Michigan Medicine, Eureka Alert, May 3, 2019 - IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans Zandra C et al. Virchows Archiv : an international journal of pathology 2019 Apr - Journal of Translational Medicine advances in Translational Genomics and Genetics Era.
Liu Wei et al. Journal of translational medicine 2019 Apr 17(1) 134 - Continuously capturing circulating cancer cells
RP Kulkarni, Science Translational Medicine, April 24, 2019 - Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.
Zeng Chang et al. Cancer communications (London, England) 2019 Mar 39(1) 12 - Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity.
Ivanov Maxim et al. Frontiers in genetics 2019 10194 - Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology.
Mathai Roshni Ann et al. Journal of clinical medicine 2019 Mar 8(3) - Breaking New Ground in Liquid Biopsy
J Lemieux, GEN News, February 21, 2019 - Liquid biopsy and minimal residual disease - latest advances and implications for cure.
Pantel Klaus, et al. Nature reviews. Clinical oncology 2019 2 0. - Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
Hahn Andrew W et al. Cancer treatment and research communications 2019 Feb 19100120
.png)
No hay comentarios:
Publicar un comentario